Stonepine Capital Management LLC Purchases 161,832 Shares of Xilio Therapeutics, Inc. $XLO

Stonepine Capital Management LLC raised its holdings in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 252.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 225,994 shares of the company’s stock after buying an additional 161,832 shares during the period. Xilio Therapeutics comprises approximately 1.2% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 24th biggest position. Stonepine Capital Management LLC’s holdings in Xilio Therapeutics were worth $2,165,023,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of XLO. Jane Street Group LLC purchased a new stake in shares of Xilio Therapeutics in the fourth quarter worth approximately $27,000. BlackRock Inc. bought a new stake in shares of Xilio Therapeutics during the 2nd quarter worth approximately $84,000. Velan Capital Investment Management LP purchased a new position in Xilio Therapeutics during the 4th quarter valued at $109,000. State Street Corp boosted its holdings in Xilio Therapeutics by 13.7% during the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after acquiring an additional 22,500 shares during the period. Finally, Renaissance Technologies LLC grew its position in Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after acquiring an additional 139,716 shares during the last quarter. Institutional investors own 54.29% of the company’s stock.

Analyst Ratings Changes

XLO has been the topic of a number of recent analyst reports. Wall Street Zen lowered Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Xilio Therapeutics Stock Performance

Shares of NASDAQ:XLO opened at $9.01 on Friday. The firm has a market cap of $59.29 million, a PE ratio of -5.49 and a beta of -0.14. The firm’s 50 day simple moving average is $9.09 and its 200-day simple moving average is $8.42. Xilio Therapeutics, Inc. has a one year low of $6.47 and a one year high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.26. The firm had revenue of $18.69 million during the quarter, compared to the consensus estimate of $12.72 million. Xilio Therapeutics had a negative net margin of 34.06% and a negative return on equity of 71.99%.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.